Search - tctmd.com

Displaying 201 - 220 of 342

Sort: Relevancy | Date

Presentation TCT 2017

Debate: After PCI in ACS, Should DAPT Potency Be De-escalated Over Time? No, Based on HORIZONS-AMI, PLATO, PEGASUS, and Other Studies!

Presenter: John A. Bittl, Freek W.A. Verheugt, Gennaro Giustino

October 30, 2017

Presentation TCT 2017

Expanding Clinical Evidence With SYNERGY: From EVOLVE II to Real-world Registries and EVOLVE DAPT

Presenter: Ioannis Iakovou, Gert Richardt, Dean J. Kereiakes

October 30, 2017

Presentation TCT 2017

Debate: After PCI in ACS, Should DAPT Potency Be De-escalated Over Time? Yes, Based on TROPICAL-ACS, TRITON, and Other Studies!

Presenter: John A. Bittl, Freek W.A. Verheugt, Dirk Sibbing

October 30, 2017

Presentation TCT 2017

DAPT Duration After BVS: Can Evidence-Based Recommendations Be Made?

Presenter: John A. Bittl, Freek W.A. Verheugt, Davide Capodanno

October 30, 2017

Presentation TCT 2017

Debate: DAPT Duration With Contemporary DES: Short (<1 Year) DAPT for Most ACS Patients!

Presenter: John A. Bittl, Freek W.A. Verheugt, Marco Valgimigli

October 30, 2017

Presentation TCT 2017

Debate: DAPT Duration With Contemporary DES: Prolonged (>1 Year) DAPT for Most ACS Patients!

Presenter: John A. Bittl, Freek W.A. Verheugt, Robert W. Yeh

October 30, 2017

Presentation TCT 2017

Debate: Making the Case for Not Pretreating ACS patients With Oral P2Y12 Receptor Inhibitors!

Presenter: John A. Bittl, Freek W.A. Verheugt, Somjot S. Brar

October 30, 2017

Presentation TCT 2017

Debate: Making the Case for Pretreating ACS patients With Oral P2Y12 Receptor Inhibitors!

Presenter: John A. Bittl, Freek W.A. Verheugt, Dimitrios Alexopoulos

October 30, 2017

Presentation TCT 2017

XIENCE Everolimus-Eluting Stents: Device Iterations, Randomized/Registry Outcomes Data in Perspective and the Move to Shorter DAPT

Presenter: Stephen G. Ellis, David E. Kandzari, Tullio Palmerini

October 30, 2017

Presentation TCT 2017

NSTEMI Case Presentation: Why the DAPT Pre-load Decision Matters

Presenter: John A. Bittl, Freek W.A. Verheugt, Patricia J. Best

October 30, 2017

Presentation TCT 2017

Should Choice of Parenteral Therapy for Primary PCI in STEMI Depend on Vascular Access?

Presenter: Michael S. Lee, Dirk Sibbing, John A. Bittl

October 30, 2017

Presentation TCT 2017

Parenteral Therapy in STEMI: Does VALIDATE Change the Equation?

Presenter: Michael S. Lee, Dirk Sibbing, David Erlinge

October 30, 2017

Presentation TCT 2017

Why I Use Cangrelor for Primary PCI in STEMI!

Presenter: Michael S. Lee, Dirk Sibbing, Dmitriy N. Feldman

October 30, 2017

Presentation TCT 2017

Why I Prefer Bivalirudin for Primary PCI in STEMI!

Presenter: Michael S. Lee, Dirk Sibbing, Uwe Zeymer

October 30, 2017

Presentation TCT 2017

Why I Prefer a Heparin Plus a GPI for Primary PCI in STEMI!

Presenter: Michael S. Lee, Dirk Sibbing, Eric R. Bates

October 30, 2017

$Why I Prefer Unfractionated Heparin Without GPI for Primary PCI in STEMI!$

Presentation TCT 2017

Why I Prefer Unfractionated Heparin Without GPI for Primary PCI in STEMI!

Presenter: Michael S. Lee, Dirk Sibbing, A. Michael Lincoff

October 30, 2017

Presentation TCT 2017

STEMI Case Presentation: Why the Choice of Patental Therapy Matters

Presenter: Michael S. Lee, Dirk Sibbing, Francesco Franchi

October 30, 2017

Presentation TCT 2017

Predicting The Future: Will the Ongoing DES 3-Month DAPT Studies With Synergy and Xience Change How We Treat High Risk Bleeding Patients?

Presenter: C. Michael Gibson, Stephan Windecker

October 30, 2017

Presentation TCT 2017

DAPT Duration: Individualized vs Generalized Approach

Presenter: Jeroen J. Bax, Michael A. Borger, Stephan Windecker, Marco Valgimigli

October 29, 2017

Presentation TCT 2017

Consideration of Prolonged DAPT After DES Deployment From Angioscopic Findings

Presenter: Takeshi Kimura, Shigeru Saito, Takafumi Ueno

October 29, 2017

Advertisement

Debate: After PCI in ACS, Should DAPT Potency Be De-escalated Over Time? No, Based on HORIZONS-AMI, PLATO, PEGASUS, and Other Studies!

Expanding Clinical Evidence With SYNERGY: From EVOLVE II to Real-world Registries and EVOLVE DAPT

Debate: After PCI in ACS, Should DAPT Potency Be De-escalated Over Time? Yes, Based on TROPICAL-ACS, TRITON, and Other Studies!

DAPT Duration After BVS: Can Evidence-Based Recommendations Be Made?

Debate: DAPT Duration With Contemporary DES: Short (<1 Year) DAPT for Most ACS Patients!

Debate: DAPT Duration With Contemporary DES: Prolonged (>1 Year) DAPT for Most ACS Patients!

Debate: Making the Case for Not Pretreating ACS patients With Oral P2Y12 Receptor Inhibitors!

Debate: Making the Case for Pretreating ACS patients With Oral P2Y12 Receptor Inhibitors!

XIENCE Everolimus-Eluting Stents: Device Iterations, Randomized/Registry Outcomes Data in Perspective and the Move to Shorter DAPT

NSTEMI Case Presentation: Why the DAPT Pre-load Decision Matters

Should Choice of Parenteral Therapy for Primary PCI in STEMI Depend on Vascular Access?

Parenteral Therapy in STEMI: Does VALIDATE Change the Equation?

Why I Use Cangrelor for Primary PCI in STEMI!

Why I Prefer Bivalirudin for Primary PCI in STEMI!

Why I Prefer a Heparin Plus a GPI for Primary PCI in STEMI!

Why I Prefer Unfractionated Heparin Without GPI for Primary PCI in STEMI!

STEMI Case Presentation: Why the Choice of Patental Therapy Matters

Predicting The Future: Will the Ongoing DES 3-Month DAPT Studies With Synergy and Xience Change How We Treat High Risk Bleeding Patients?

DAPT Duration: Individualized vs Generalized Approach

Consideration of Prolonged DAPT After DES Deployment From Angioscopic Findings

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content